The predictive value of body protein for chemotherapy-induced toxicity

Cancer

Volumn 88, Issue 4, 2000, Pages 796-803

  Aslani, Alireza ^a   Smith, Ross C ^a   Allen, Barry J ^a   Pavlakis, Nicholas ^a   Levi, John A ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Body surface area; Chemotherapy; Drug dosing; Medical oncology; Nitrogen index

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; NITROGEN;

ADULT; AGED; ARTICLE; BODY SURFACE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TOXICITY;

ADENOCARCINOMA; ADULT; AGED; ANTHROPOMETRY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; NITROGEN; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 0034651913     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO;2-P     Document Type: Article

References (46)

1. Early Breast Cancer Trialists' Collaboration Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988;319:1681-92.
2. Crown J, Norton L. Adjuvant systemic therapy for early breast cancer. Semin Surg Oncol 1991;7:283-90.
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
4. Engelsman E, Klijn JC, Rubens RD, et al. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III trial (10808). Eur J Cancer 1991;27:966-70.
5. Wong K, Henderson IC. Management of metastatic breast cancer. World J Surg 1994;18:98-111.
6. Early Breast Cancer Trialists' Collaboration Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
7. Brincker H, Mouridsen HT, Andersen KW. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with Stage II breast cancer. Breast Cancer Res Treat 1983;3:91-5.
8. Wood WC, Weiss RB, Tormey DC, et al. A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive Stage II breast cancer: a CALGB Study. World J Surg 1985;9:714-8.
9. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983;1:2-10.
10. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
11. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 [prior annotation incorrect]. J Clin Oncol 1990;8:1483-96.
12. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9:2134-40.
13. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991;9:1124-30.
14. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304: 10-5.
15. Fisher BJ, Perera FE, Cooke AL, Opeitum A, Stitt L. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 1998;42:117-23.
16. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90(16):1205-11.
17. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6.
18. Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, Phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993;82:2329-39.
19. Ribas A, Albanell J, Bellmunt J, et al. Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. Acta Oncol 1997;36:701-4.
20. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in Stage II and III breast cancer. Br J Cancer 1997;75:301-5.
21. de Graaf H, Willemse PH, Bong SB, et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 1996;53:289-94.
22. Ribas A, Albanell J, Bellmunt J, et al. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 1996;14:1573-80.
23. de Graaf H, Willemse PHB, Barbara Bong S, Piersma H, Tjabbes T, van Veelen H, et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 1996;53:289-94.
24. Fisher DC, Peters WP. Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. Curr Opin Hematol 1994;1(3):221-7.
25. Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, et al. for CALGB, SWOG, and NCIC. A prospective, randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstract]. Proc Am Soc Clin Oncol 1999;18:2.
26. Bezwoda WR. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) vs standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1999;18:4.
27. Du Bois EF, Du Bois D. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-71.
28. Ratain MJ. Body surface area as a basis for dosing of anticancer agents: science, myth or habit? J Clin Oncol 1998; 16(7):2297-8.24.
29. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-611.
30. Monk DN, Plank LD, Franch Arcas G, Finn PJ, Streat SJ, Hill GL. Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma. Ann Surg 1996;223:395-405.
31. Finn PJ, Plank LD, Clark MA, Connolly AB, Hill GL. Progressive cellular dehydration and proteolysis in critically ill patients. Lancet 1996;347:654-6.
32. Smith KL, Tisdale MJ. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer 1993;67:680-5.
33. Durnin JV, Rahaman MM. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr 1967;21:681-9.
34. Durnin JV, Womersley J. Total body fat, calculated from body density, and its relationship to skinfold thickness in 571 people aged 12-72 years. Proc Nutr Soc 1973;32:45A.
35. Durnin JV, Armstrong WH, Womersley J. An experimental study on the variability of measurements of skinfold thicknesses by three observers on twenty-three young women and twenty-seven young men. Proc Nutr Soc 1971;30:9A-10A.
36. Allen BJ, Blagojevic N, Delaney I, et al. The role of body protein studies in clinical trials. Basic Life Sci 1990;55:155-69.
37. Pollock CA, Ibels LS, Allen BJ, et al. Total body nitrogen as a prognostic marker in maintenance dialysis. J Am Soc Nephrol 1995;6:82-8.
38. Allen BJ, Blagojevic N, McGregor BJ, et al. In vivo determination of protein in malnourished patients. In: Ellis KJ, Yasumura S, Morgan WD, editors. In vivo body composition studies. London: Institute of Physical Sciences in Medicine, 1987:77-82.
39. Baur LA, Knight JF, Crawford BA, et al. Total body nitrogen in children with chronic renal failure and short stature. Eur J Clin Nutr 1994;48:433-41.
40. Baur LA, Waters DL, Allen BJ, Blagojevic N, Gaskin KJ. Nitrogen deposition in malnourished children with cystic fibrosis. Am J Clin Nutr 1991;53:503-11.
41. Blagojevic N, Allen BJ, Gaskin KJ, Baur LA. Determination of total body water by Fourier transform infrared analysis. Australas Phys Eng Sci Med 1990;13:110-6.
42. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
43. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
44. Fagan TJ. Nomogram for Bayes theorem. N Engl J Med 1975;293:257.
45. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271:703-7.
46. Georgiadis MS, Steinberg SM, Hankins LA, Ihde DC, Johnson BE. Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 1995; 87:361-6.